CLINICAL UTILITY OF AXUMIN PET/MRI IMAGING TWO YEARS FOLLOWING FOCAL CRYO-ABLATION (FCA) OF PROSTATE CANCER

Condition: Prostate Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT04009083

Sponsor: NYU Langone Health

Eligibility:

• Age: minimum 18 Years maximum 100 Years
• Gender: Male

Inclusion Criteria:

• FCA at NYU Langone Health performed at least two years prior to study enrollment by Drs. Lepor or Wysock.
• No prostate cancer specific treatment following FCA
• Consented to undergo reflex MRI and prostate biopsy two years following FCA.

Exclusion Criteria:

• Any contraindication to prostate biopsy
• Prior allergic reaction to 18F-Fluciclovine
• Patient refuses MRI and prostate biopsy two years following FCA.

View trial on ClinicalTrials.gov